Cancer treatment developer, Sirtex Medical
(ASX:SRX) has launched a new investigator led study on the most common form of primary liver cancer.
The study will test the anit-tumour efficacy of Opdivo after Sirtex’s SIR-Spheres has been used in candidates.
The primary endpoint is safety and the key secondary endpoint is overall survival.
The study is expected to recruit 40 patients.
Shares in Sirtex Medical
(ASX:SRX) are trading 0.97 per cent lower to $14.30.
